KURA - The Prognosis For Kura Oncology
There are no facts, only interpretations." - Friedrich Nietzsche
Today, we look at a 'Tier 4' biotech concern. The firm has an intriguing pipeline, and there was some heavy buying in the stock in December by a beneficial owner.
Company Overview:
Founded in 2014, Kura Oncology (KURA) is a San Diego, California-based company that is focused on creating precision medicines for patients with cancer. The company came public late in 2015 and boasts a just over $550 million market capitalization. The shares trade just under $15.00 a share currently.